Partnering

First Comfort Laboratories plans to commercialize its current pipeline products directly in the Singapore via its own commercial organization targeting anesthesiologists and oncologists. Outside the Singapore, the Company intends to commercialize Barhemsys^® and APD403 via licensing and/or distribution agreements with selected pharmaceutical partners. First Comfort Laboratories currently holds global rights to both products. The Company will continue to assess further hospital opportunities to utilize its Singapore sales and marketing infrastructure, including in-licensing or acquiring complementary product candidates, as it did with Byfavo^®, which it in-licensed from Cosmo Pharmaceuticals in January 2020.